Back to Search
Start Over
Efficacy comparison of concurrent chemoradiotherapy with nedaplatin and cisplatin in inoperable locally-advanced non-small cell lung cancer
- Source :
- Pharmaceutical Care and Research. 20:355-376
- Publication Year :
- 2020
- Publisher :
- Publishing House of Pharmaceutical Care and Research, 2020.
-
Abstract
- Objective: To compare the efficacy and safety of concurrent chemoradiotherapy with nedaplatin and cisplatin in inoperative locally-advanced non-small cell lung cancer(NSCLC).Methods: Eighty patients with locally-advanced NSCLC treated in Guanyun County People’s Hospital,Lianyungang,Jiangsu Province,from January 2015 to January 2019 were enrolled as study subjects,and were randomly divided into the nedaplatin group and the cisplatin group,each consisting of 40 patients.The patients in the 2 groups were treated with linear accelerator 6 MV high energy X-ray and 3D-CRT,5 times a week for a succession of 6 weeks,with a total dosage of 55-66 Gy.Then,the patients were given paclitaxel(155 mg/m2) intravenously for 3 hours in the first day after radiotherapy,and the patients in the cisplatin group were treated with cisplatin(80 mg/m2) intravenously for 3 to 4 days,and the patients in the nedaplatin group were given nedaplatin(80 mg/m2) intravenously also for 3 to 4 days.The efficacy,the levels of such serum tumor markers as carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron specific enolase(NSE) and cytokeratin fragment antigen 21-1(CYFRA21-1),as well as the rate of adverse drug reactions(ADRs) were compared between the 2 groups.Results: There was no statistical significance in remission rate and disease control rate,when comparisons were made between the 2 groups(P>0.05).After treatment,CEA,CA125,NSE and CYFRA21-1 levels in the 2 groups were significantly lower than those before treatment(P0.05).However,NSE and CYFRA21-1 levels in the patients of the nedaplatin group were significantly lower than those of the cisplatin group(P
- Subjects :
- Pharmacology
Oncology
Cisplatin
medicine.medical_specialty
business.industry
Locally advanced
Pharmaceutical Science
medicine.disease
Concurrent chemoradiotherapy
chemistry.chemical_compound
chemistry
Internal medicine
Drug Discovery
medicine
Nedaplatin
Non small cell
Lung cancer
business
medicine.drug
Subjects
Details
- ISSN :
- 16712838
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Pharmaceutical Care and Research
- Accession number :
- edsair.doi...........8362a8573c21016634f2c2fe7ffad768